ClinPGx Blog (Page 25)

Sign in Subscribe

More issues

Response to the American Academy of Pediatrics statement on codeine: let's consider CYP2D6

The American Academy of Pediatrics (AAP) issued a statement last Tuesday that codeine should not be used in children. As discussed in the article, pharmacogenetic variation can affect response to codeine, which is metabolized into its active form by the hepatic enzyme CYP2D6. Thus poor metabolizers are unlikely to benefit

Clinical implementation of PGx discussed in JAMA article

A recent article in the Journal of the American Medical Association (JAMA) discusses the current state of pharmacogenetic (PGx) implementation in the clinic. The article notes that clinical uptake of pharmacogenetics has been slow, despite data from the American Medical Association showing that 98% of the more than 10,000

Ivacaftor pathway, pharmacokinetics/pharmacodynamics published in Pharmacogenetics and Genomics

The PharmGKB summary of the pharmacokinetics and pharmacodynamics of ivacaftor has been published in Pharmacogenetics and Genomics. Ivacaftor is approved for use in patients who carry particular variants in the CFTR gene. By repotentiating the CFTR ion channel, ivacaftor targets the underlying cause of some forms of cystic fibrosis. Ivacaftor

NIH Request for Information: Metrics to Assess Value of Biomedical Digital Repositories

NIH has issued a Request for Information to gather input about metrics to assess the impact and value of biomedical digital data repositories, including deposition repositories and knowledgebases. NIH is interested in collecting information about the usage, quality of data, quality of service and other aspects of existing repositories. Community

CPIC and PGx discussed in recent GEN article

A recent article in Genetic Engineering & Biotechnology News (GEN) discusses the future of pharmacogenetics in the context of clinical practice. The article notes that personalized medicine will likely be enacted through the work of intermediary groups, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), who can help clinicians keep

Nature Outlook: Precision Medicine on Pharmacogenetics highlights its status, promise, and burdens

An outlook on precision medicine in Nature discusses the status, promise, and burdens of the implementation of pharmacogenetic knowledge into clinical care. It highlights the PGEN4Kids program at St Jude, which is implementing CPIC recommendations in a preemptive genetic testing program for pediatric patients. As discussed in the article, CPIC

Join the CPT Webinar on CPIC Guidelines: Thursday, September 22, 12-1pm EDT

Click here to register.

PharmCAT poster to be presented at ASHG

At the American Society of Human Genetics annual meeting in October, PharmGKB will be presenting the new Pharmacogenomics Clinical Annotation Tool (PharmCAT) with our colleague, Dr. Marylyn Ritchie, who is pictured on the home page of the meeting website (http://www.ashg.org/2016meeting/). We look forward to seeing everyone

CPIC Meeting at ASCPT on March 15, 2017

The Clinical Pharmacogenetics Implementation Consortium(CPIC®) Meeting will be held on March 15, 2017, in conjunction with the 2017 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) on March 15-18, 2017 (Washington, DC). The one-day symposium is organized by the Clinical Pharmacogenetics Implementation Consortium (CPIC®) (cpicpgx.

CPIC Seeks Feedback on Recommendation Strength and Gene/Drug Pair Level Definitions

CPIC is proposing changes to CPIC Guideline grades for strength of recommendation and for definitions of CPIC Levels of gene/drug pairs. Based on a review of other practices and challenges presented by some CPIC gene/drug pairs, it is recommended that the option "no recommendation" be added